Biomea Fusion, Inc. (BMEA)
NASDAQ: BMEA · IEX Real-Time Price · USD
12.24
-0.54 (-4.23%)
At close: May 17, 2024, 4:00 PM
12.85
+0.61 (4.98%)
After-hours: May 17, 2024, 6:07 PM EDT
Company Description
Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases.
Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes.
The company was incorporated in 2017 and is headquartered in Redwood City, California.
Biomea Fusion, Inc.
Country | United States |
Founded | 2017 |
IPO Date | Apr 16, 2021 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 110 |
CEO | Thomas Andrew Butler |
Contact Details
Address: 900 Middlefield Road, 4th Floor Redwood City, California 94063 United States | |
Phone | (650) 980-9099 |
Website | biomeafusion.com |
Stock Details
Ticker Symbol | BMEA |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
IPO Price | $17.00 |
CIK Code | 0001840439 |
CUSIP Number | 09077A106 |
ISIN Number | US09077A1060 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Thomas Andrew Butler | Co-Founder, Chairman and Chief Executive Officer |
Ramses M. Erdtmann | Co-Founder, President, Chief Operating Officer and Director |
Franco Valle | Chief Financial Officer and Principal Accounting Officer |
Heow Tan | Chief Technology and Quality Officer |
Naomi Cretcher | Chief People Officer |
Dr. Thorsten Kirschberg Ph.D. | Executive Vice President of Chemistry |
Dr. Stephan Morris M.D. | Chief Development Officer |
Ravi Upasani | Executive Vice President of Intellectual Property |
Dr. Juan Pablo Frias M.D. | Chief Medical Officer |
Caroline Perez- Dupont | Senior Vice President of Contracts |
Latest SEC Filings
Date | Type | Title |
---|---|---|
May 2, 2024 | 8-K | Current Report |
May 2, 2024 | 10-Q | Quarterly Report |
Apr 26, 2024 | ARS | Filing |
Apr 26, 2024 | DEF 14A | Other definitive proxy statements |
Apr 10, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
Apr 1, 2024 | 8-K | Current Report |
Apr 1, 2024 | 8-K | Current Report |
Mar 28, 2024 | 10-K | Annual Report |
Mar 7, 2024 | 8-K | Current Report |
Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |